Investment analysts at Guggenheim decreased their price target on shares of Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), from $15.00 to $13.00 in a note issued to investors on Friday, AnalystRatings.Net reports. Guggenheim’s target price would suggest a potential upside of 129.68% from the company’s current price. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), weekly performance is -18.02%. On last trading day company shares ended up $4.55. Analysts mean target price for the company is $13.38. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), distance from 50-day simple moving average (SMA50) is -31.04%.
On May 12, 2014, Onconova Therapeutics Inc (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, provided a corporate update and reported financial results for the first quarter ended March 31, 2014. Onconova Therapeutics Inc (NASDAQ:ONTX), fell 1.95% in last trading session and ended the day on $4.52. ONTX, return on assets is -72.70%. Onconova Therapeutics Inc (NASDAQ:ONTX), quarterly performance is -48.58%.
On May 14, 2014, Concert Pharmaceuticals Inc (NASDAQ:CNCE), reported financial results for the first quarter of 2014. Cash, cash equivalents and investments as of March 31, 2014, totaled $108.0 million as compared to $32.7 million as of December 31, 2013. In the first quarter of 2014, Concert announced the closing of its initial public offering, raising net proceeds of $83.1 million including the exercise of the underwriters’ overallotment option on March 3, 2014. Based upon Concert’s current operating budget, the Company expects that its cash, cash equivalents and investments as of March 31, 2014 will be sufficient to fund operations into 2016. Concert Pharmaceuticals Inc (NASDAQ:CNCE), shares moved down 3.21% in last trading session and was closed at $7.23, while trading in range of $7.12 – 7.54. Concert Pharmaceuticals Inc (NASDAQ:CNCE), year to date (YTD) performance is -49.01%.
On May 14, 2014, ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, provided information on the data presentations on Company and partner compounds to be made at the 2014 American Society of Clinical Oncology (ASCO) annual meeting, which will be held May 30-June 3 in Chicago, IL. New clinical data are being presented on ImmunoGen wholly owned compounds, IMGN529 and IMGN853, as well as on partner compounds SAR3419, SAR650984 and Kadcyla® (ado-trastuzumab emtansine). ImmunoGen, Inc. (NASDAQ:IMGN), ended the last trading day at $10.70. Company weekly volatility is calculated as 5.13% and price to cash ratio as 5.60. ImmunoGen, Inc. (NASDAQ:IMGN), showed a negative weekly performance of 10.16%.
Leave a Reply